Resource Summary Report

Generated by RRID on Aug 27, 2026

HPAC

RRID:CVCL_3517
Type: Cell Line

Proper Citation

RRID:CVCL_3517

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3517

Proper Citation: RRID:CVCL_3517

Description: Cell line HPAC is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Pancreatic adenocarcinoma

Defining Citation: PMID:15367885, PMID:20215515, PMID:20418756, PMID:22460905, PMID:22585861, PMID:25167228, PMID:25485619, PMID:25877200, PMID:25939163, PMID:25984343, PMID:26216984, PMID:26589293, PMID:27259358, PMID:27397505, PMID:30894373, PMID:31068700, PMID:35839778

Comments: Characteristics: Established from a nude mouse xenograft (ATCC=CRL-2119)., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HPAC

Synonyms: Hpac

Cross References: BTO:BTO_0004121, CLO:CLO_0003814, EFO:EFO_0002197, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2119, BCRC:60495, BioSample:SAMN03472247, BioSample:SAMN10987698, cancercelllines:CVCL_3517, CCRID:1101HUM-PUMC000189, Cell_Model_Passport:SIDM00670, ChEMBL-Cells:CHEMBL3308388, ChEMBL-Targets:CHEMBL612595, CLS:305309,

Cosmic:913306, Cosmic:1571784, Cosmic:1995444, Cosmic:2434094, Cosmic-CLP:1298136, DepMap:ACH-000270, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1298136, GEO:GSM206509, GEO:GSM621897, GEO:GSM784701, GEO:GSM887089, GEO:GSM888160, GEO:GSM1024401, GEO:GSM1374545, GEO:GSM1669892, IARC_TP53:21070, IGRhCellID:HPAC, LiGeA:CCLE_795, LINCS_LDP:LCL-1735, PharmacoDB:HPAC_564_2019, PRIDE:PXD003198, PRIDE:PXD030304, PRIDE:PXD032263, Progenetix:CVCL_3517, PubChem_Cell_line:CVCL_3517, Wikidata:Q54890226

ID: CVCL_3517

Record Creation Time: 20220427T220440+0000

Record Last Update: 20260815T233941+0000

Ratings and Alerts

No rating or validation information has been found for HPAC.

No alerts have been found for HPAC.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 56 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Kamgar M, et al. (2026) Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma. Cancer research, 86(8), 2042.

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. Cell, 189(10), 2898.

Miyan J, et al. (2026) The combination of BCL-xL PROTAC and mTOR inhibitor sensitizes pancreatic ductal adenocarcinoma to KRAS G12D inhibitor treatment by enhancing apoptosis induction. bioRxiv : the preprint server for biology.

Ning W, et al. (2026) A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer. Cell reports. Medicine, 7(4), 102688.

Gong D, et al. (2026) GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma. Cell reports, 45(5), 117314.

Bajgain P, et al. (2026) Engineering functionality-optimized fully human B7-H3 CAR T cells for enhanced solid tumor therapy. Cell reports. Medicine, 7(5), 102782.

Roach MK, et al. (2026) Vertical inhibition of the autophagy pathway impairs growth and enhances sensitivity to mTORC1 inhibition in pancreatic ductal adenocarcinoma. bioRxiv : the preprint server for biology.

Xie L, et al. (2026) Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor. Cancer discovery, 16(5), 895.

Baars B, et al. (2026) RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors. Molecular cancer research : MCR, 24(1), 60.

Woo SM, et al. (2026) Inhibiting Fatty Acid Oxidation Reverses Autophagy-Mediated Acquired Chemotherapy Resistance in Pancreatic Ductal Adenocarcinoma. Cancer research, 86(13), 3194.

Murr J, et al. (2026) The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. MedComm, 7(6), e70794.

Takano K, et al. (2026) DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity. Molecular cancer therapeutics, 25(1), 7.

Burge RA, et al. (2026) KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment. Cancer research, 86(8), 1868.

Shen S, et al. (2026) ALDH1A3 promotes the lung metastatic organotropism of pancreatic ductal adenocarcinoma through semaphorin signaling. iScience, 29(6), 115950.

Zhao B, et al. (2025) PLK1 blockade enhances the anti-tumor effect of MAPK inhibition in pancreatic ductal adenocarcinoma. Cell reports, 44(4), 115541.

Lee DKC, et al. (2025) ITGAV and SMAD4 influence the progression and clinical outcome of pancreatic ductal adenocarcinoma. Molecular oncology.

Wittenzellner K, et al. (2025) Label-free single-cell phenotyping to determine tumor cell heterogeneity in pancreatic cancer in real time. JCI insight, 10(13).

Li H, et al. (2025) Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy. Cell reports. Medicine, 6(2), 101927.

Zhang W, et al. (2025) RACK1 attenuates pancreatic tumorigenesis by suppressing acinar-to-ductal metaplasia through inflammatory signaling modulation. Cellular oncology (Dordrecht, Netherlands).

Maki R, et al. (2025) Efficacy of SOAT1 Inhibitors Against Pancreatic Cancer with TP53 Mutations. Annals of surgical oncology, 32(9), 7025.